⚕ GalenOps CRO console
← SITE002 (USA)

SITE002-0188

completed
Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE002 (USA) (Dr. Nolan) · consented 2022-10-08
Adverse events
8
Serious AEs
1
Open data queries
0
Luna dropout signal
–

Adverse events

moderate assessed 2026-08-18

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-11-24 (study day 29); relationship: N

moderate assessed 2026-08-18

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-11-26 (study day 31); relationship: not assessed

severe serious assessed 2026-08-18

Grade 4 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-04-11 (study day 167); relationship: N; serious criteria: life-threatening

moderate assessed 2026-08-18

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-04-25 (study day 181); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-06-20 (study day 237); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-07-10 (study day 257); relationship: Y

mild assessed 2026-08-18

Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-08-21 (study day 299); relationship: not assessed

severe assessed 2026-08-18

Grade 3 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-11-15 (study day 385); relationship: not assessed

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.